Verona Pharma (NASDAQ:VRNA) Now Covered by Wells Fargo & Company
Equities research analysts at Wells Fargo & Company began coverage on shares of Verona Pharma (NASDAQ:VRNA – Get Free Report) in a research note issued on Thursday, MarketBeat reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 56.20% […]
More Stories
Greenland Lawmakers Approve US, Denmark Security Deal
By Jill McLaughlin Greenland lawmakers unanimously approved a security agreement Nov. 3 with the United States and Denmark that will...
The World Looks Upside Down…But It Isn’t
By Louis Navellier The world seems to have been turned upside down, and we are suddenly all living in “Opposite...
US Oil Prices Fall More Than 7 Percent on Iran Peace Talks
By Andrew Moran Crude oil prices fell sharply to start the trading week on hopes of peace talks with Iran....
Appeals Court Allows Trump Admin Effort Targeting Noncitizen Voting
By Zachary Stieber A federal appeals court on Nov. 3 reinstated a decision that stays a restraining order that had...
US Manufacturing Expands for 10th Straight Month Amid High Input Costs
By Bill Pan U.S. manufacturing activity strengthened in October as new orders increased, although raw materials became more expensive and...
America Votes: What to Expect
By Lawrence Wilson Democrats appear poised to win control of the House and possibly the Senate on Nov. 3 as...